Laurus Labs schedules Q2 FY27 earnings call for October 29
- Laurus Labs will hold its Q2 and H1 FY27 earnings conference call on October 29, 2026
- The call is scheduled for 5:00 pm IST and hosted by DAM Capital Advisors
- International dial-ins are available for investors in Singapore, Hong Kong, USA, and UK
- The company reported ₹6,813 crore in annual revenue during FY26

*this image is generated using AI for illustrative purposes only.
Laurus Labs Limited will host a conference call on Thursday, October 29, 2026, at 5:00 pm IST to discuss its second quarter and first half FY27 financial results. The event includes an interactive Q&A session with management.
The call is organized in collaboration with DAM Capital Advisors. Investors and analysts can join via primary and secondary dial-in numbers provided in the official notice. International access is available through toll-free numbers in Singapore, Hong Kong, USA, and UK.
Call Logistics
Participants can access the earnings discussion using the following details:
| Detail | Information |
|---|---|
| Date | October 29, 2026 |
| Time | 5:00 pm IST |
| Host | DAM Capital Advisors |
| Primary Dial-in | +91 22 6280 1384 |
| Secondary Dial-in | +91 22 7115 8285 |
International dial-in options include Singapore (+8001012045), Hong Kong (+800964448), USA (+18667462133), and UK (+08081011573). A Diamond Pass event link is also referenced for digital participation.
Company Profile
Laurus Labs is a research-driven pharmaceutical manufacturing organization specializing in APIs and intermediates. The company holds global leadership positions in anti-retroviral, oncology, cardiovascular, and gastro therapeutics. It operates as a Contract Development and Manufacturing Organization (CDMO) with facilities approved by global regulators including the USFDA, WHO, and EMA.
The company employs over 8,126 people, including more than 3,134 scientists, across 15 facilities. In FY26, Laurus Labs generated ₹6,813 crore in annual revenue.
Historical Stock Returns for Laurus Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.06% | +3.11% | +6.91% | +84.33% | +135.36% | 0.0% |
How will Laurus Labs' Q2 FY27 performance compare to its FY26 revenue baseline of ₹6,813 crore?
What specific growth drivers in the CDMO segment are expected to influence the upcoming financial results?
How might recent regulatory inspections by the USFDA or EMA impact Laurus Labs' future capacity utilization?


































